Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Fall on the Road
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Agios Pharmaceuticals
(NQ:
AGIO
)
29.29
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
29.29
Bid (Size)
24.00 (1)
Ask (Size)
46.86 (2)
Prev. Close
29.29
Today's Range
29.29 - 29.29
52wk Range
19.80 - 35.50
Shares Outstanding
58,951,469
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
February 23, 2024
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.
Via
Investor's Business Daily
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Performance
YTD
+28.30%
+28.30%
1 Month
+8.08%
+8.08%
3 Month
+25.98%
+25.98%
6 Month
+15.04%
+15.04%
1 Year
+28.86%
+28.86%
More News
Read More
Earnings Preview: Agios Pharmaceuticals
February 14, 2024
Via
Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Via
InvestorPlace
Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today?
January 03, 2024
Via
Benzinga
Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug
January 03, 2024
Via
Investor's Business Daily
RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know
June 27, 2023
Via
Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
May 15, 2023
Via
Benzinga
Agios Pharmaceuticals's Return On Capital Employed Insights
February 24, 2023
Via
Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
November 17, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 03, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 03, 2024
Via
InvestorPlace
Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat
June 26, 2023
Via
Benzinga
Why Shares of Schrödinger Rose This Week
June 16, 2023
Via
The Motley Fool
7 Biotech Stocks to Buy for 100% Returns
April 09, 2023
Via
InvestorPlace
7 Biotech Stocks That Could Be the Next Big Thing
March 15, 2023
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
December 24, 2022
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
November 17, 2022
Via
Benzinga
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
November 11, 2022
Via
Benzinga
Agios Pharmaceuticals: Q3 Earnings Insights
November 03, 2022
Via
Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
September 02, 2022
Via
Investor's Business Daily
Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday
September 01, 2022
Via
Benzinga
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
September 02, 2022
Via
Benzinga
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
September 01, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.